Ally Bridge Group »

Merus N V shares owned by Ally Bridge Group

Quarter-by-quarter ownership of Merus N V (MRUS) shares owned by Ally Bridge Group from 13F filings

Historical chart of Ally Bridge Group investment in Merus N V

Tip: Access up to 7 years of quarterly data

All positions including Merus N V held by Ally Bridge Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Merus N V by Ally Bridge Group

Quarter filed Position value Share count Share price at filing
2023-09-30 $5.2M 221k 23.58
2023-06-30 $5.2M 199k 26.33
2023-03-31 $5.1M 276k 18.40

More positions owned by Ally Bridge Group

Moonlake Immunotherapeutics Class A Ord (MLTX)
Xenon Pharmaceuticals (XENE)
Intra Cellular Therapies (ITCI)
Axsome Therapeutics (AXSM)
Apellis Pharmaceuticals (APLS)
Cytokinetics Com New (CYTK)
Merus N V (MRUS)
Amylyx Pharmaceuticals (AMLX)
Geron Corporation (GERN)
Ardelyx (ARDX)
Ambrx Biopharma Sponsored Ads
Mirati Therapeutics
Jasper Therapeutics
Black Diamond Therapeutics (BDTX)
Praxis Precision Medicines I

View all positions for Ally Bridge Group

Top funds holding Merus N V

Commodore Capital
Federated Investors
Samlyn Capital
Deerfield Management Company
BVF
VR Adviser
Wellington Management Company
Boxer Capital
Franklin Resources
Balyasny Asset Management
Medicxi Ventures Management
Lynx1 Capital Management
venBio Select Advisor
Frazier Life Sciences Management
Fairmount Funds Management

View all funds holding Merus N V